Study of YOLT-202 in the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

EARLY_PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 18, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

March 31, 2027

Conditions

Alpha-1 Antitrypsin Deficiency (AATD)

Interventions

DRUG

YOLT-202

The IP is administered intravenously at the predetermined dose; Administration frequency: Once

Trial Locations (1)

Ren Ji Hospital Affiliated to Shanghai Jiao Tong University, Shanghai

All Listed Sponsors

lead

RenJi Hospital

OTHER

NCT07193615 - Study of YOLT-202 in the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) | Biotech Hunter | Biotech Hunter